<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680086</article-id><article-id pub-id-type="doi">10.3390/v16121923</article-id><article-id pub-id-type="publisher-id">viruses-16-01923</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Sequence Analysis of microRNAs Encoded by Simian Lymphocryptoviruses</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Yan</given-names></name><xref rid="af1-viruses-16-01923" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1646-8102</contrib-id><name><surname>Fachko</surname><given-names>Devin N.</given-names></name><xref rid="af1-viruses-16-01923" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Helen L.</given-names></name><xref rid="af2-viruses-16-01923" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Sacha</surname><given-names>Jonah B.</given-names></name><xref rid="af1-viruses-16-01923" ref-type="aff">1</xref><xref rid="af2-viruses-16-01923" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2967-9478</contrib-id><name><surname>Skalsky</surname><given-names>Rebecca L.</given-names></name><xref rid="af1-viruses-16-01923" ref-type="aff">1</xref><xref rid="af2-viruses-16-01923" ref-type="aff">2</xref><xref rid="c1-viruses-16-01923" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Jin</surname><given-names>Ling</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-16-01923"><label>1</label>Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA; <email>yanc@ohsu.edu</email> (Y.C.); <email>fachko@ohsu.edu</email> (D.N.F.); <email>sacha@ohsu.edu</email> (J.B.S.)</aff><aff id="af2-viruses-16-01923"><label>2</label>Oregon National Primate Research Center, Beaverton, OR 97006, USA; <email>wuhe@ohsu.edu</email></aff><author-notes><corresp id="c1-viruses-16-01923"><label>*</label>Correspondence: <email>skalsky@ohsu.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>16</volume><issue>12</issue><elocation-id>1923</elocation-id><history><date date-type="received"><day>19</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>09</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>10</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Lymphocryptoviruses (LCVs) are ubiquitous gamma-herpesviruses that establish life-long infections in both humans and non-human primates (NHPs). In immunocompromised hosts, LCV infections are commonly associated with B cell disorders and malignancies such as lymphoma. In this study, we evaluated simian LCV-encoded small microRNAs (miRNAs) present in lymphoblastoid cell lines (LCLs) derived from a Mauritian cynomolgus macaque (<italic toggle="yes">Macaca fascicularis</italic>) with cyLCV-associated post-transplant lymphoproliferative disease (PTLD) as well as the viral miRNAs expressed in a baboon (<italic toggle="yes">Papio hamadryas</italic>) LCL that harbors CeHV12. Via sequence comparisons, we further predicted viral miRNAs encoded by LCVs that infect two additional NHP species: stump-tailed macaques (<italic toggle="yes">Macaca arctoides</italic>) and bonobos (<italic toggle="yes">Pan paniscus</italic>). Together, these species represent two arms of the primate phylogeny: Hominoids (<italic toggle="yes">Pan</italic>) and Old-World monkeys (<italic toggle="yes">Macaca</italic>, <italic toggle="yes">Papio</italic>). Through our analysis, we defined sequences for &#x0003e;95 viral miRNAs encoded by these four NHP LCVs. Our study provides the most comprehensive annotation of NHP LCV miRNAs to date, yielding a resource for developing sequence-specific reagents to detect these molecules. Importantly, we further demonstrate that cyLCV miRNAs can be detected in circulation in vivo and have biomarker potential for LCV-related PTLD.</p></abstract><kwd-group><kwd>lymphocryptovirus</kwd><kwd>herpesvirus</kwd><kwd>microRNAs</kwd><kwd>biomarkers</kwd></kwd-group><funding-group><award-group><funding-source>National Institutes of Health</funding-source><award-id>AI129703</award-id><award-id>AI143620</award-id></award-group><award-group><funding-source>Oregon National Primate Research Center (ONPRC)</funding-source><award-id>P51 OD011092</award-id></award-group><funding-statement>This work was supported in part by National Institutes of Health, grant AI129703, awarded to J.B.S.; grant P51 OD011092, awarded to the Oregon National Primate Research Center (ONPRC); and National Institutes of Health, grant AI143620, awarded to R.L.S.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-16-01923"><title>1. Introduction</title><p>Lymphocryptoviruses (LCVs) are ubiquitous gamma-herpesviruses that establish life-long persistent infections in their primate hosts [<xref rid="B1-viruses-16-01923" ref-type="bibr">1</xref>]. As infectious pathogens, LCVs are highly successful at infecting their hosts, likely due to their oral route of transmission combined with the shedding of high viral loads in saliva [<xref rid="B1-viruses-16-01923" ref-type="bibr">1</xref>]. Epstein&#x02013;Barr virus (EBV) represents the human counterpart of the LCV family and, besides infectious mononucleosis, is linked to several lymphoproliferative diseases such as post-transplant lymphoproliferative disorders (PTLD) and malignancies such as Burkitt&#x02019;s lymphoma (BL), Hodgkin lymphoma, and non-Hodgkin lymphoma [<xref rid="B2-viruses-16-01923" ref-type="bibr">2</xref>,<xref rid="B3-viruses-16-01923" ref-type="bibr">3</xref>].</p><p>Despite the identification of EBV in pediatric BL samples over 60 years ago [<xref rid="B2-viruses-16-01923" ref-type="bibr">2</xref>,<xref rid="B3-viruses-16-01923" ref-type="bibr">3</xref>], there are still no EBV-specific FDA-approved vaccines or therapies [<xref rid="B4-viruses-16-01923" ref-type="bibr">4</xref>]. Preclinical animal models of EBV infection and pathogenesis are necessary for the development of vaccines and virus-specific therapeutics; however, relevant small animal models for EBV are limited, and thus, studies predominantly rely on large animal models such as nonhuman primates (NHPs) in order to fully recapitulate all aspects of EBV infection, tissue tropism, immune responses, pathogenesis, and transmission [<xref rid="B1-viruses-16-01923" ref-type="bibr">1</xref>,<xref rid="B4-viruses-16-01923" ref-type="bibr">4</xref>,<xref rid="B5-viruses-16-01923" ref-type="bibr">5</xref>,<xref rid="B6-viruses-16-01923" ref-type="bibr">6</xref>,<xref rid="B7-viruses-16-01923" ref-type="bibr">7</xref>,<xref rid="B8-viruses-16-01923" ref-type="bibr">8</xref>,<xref rid="B9-viruses-16-01923" ref-type="bibr">9</xref>]. Notably, LCVs naturally infect humans and other hominids, including both Old and New World NHPs, and thus, LCV infection in macaques is often used to model EBV pathogenesis [<xref rid="B1-viruses-16-01923" ref-type="bibr">1</xref>,<xref rid="B9-viruses-16-01923" ref-type="bibr">9</xref>] and accurately evaluate targets for EBV vaccine development [<xref rid="B10-viruses-16-01923" ref-type="bibr">10</xref>,<xref rid="B11-viruses-16-01923" ref-type="bibr">11</xref>]. Akin to EBV infection, LCVs in immunocompromised macaques are associated with lymphoproliferative diseases such as PTLD, lymphoid hyperplasia, and B cell lymphoma [<xref rid="B1-viruses-16-01923" ref-type="bibr">1</xref>,<xref rid="B6-viruses-16-01923" ref-type="bibr">6</xref>,<xref rid="B7-viruses-16-01923" ref-type="bibr">7</xref>,<xref rid="B9-viruses-16-01923" ref-type="bibr">9</xref>,<xref rid="B12-viruses-16-01923" ref-type="bibr">12</xref>,<xref rid="B13-viruses-16-01923" ref-type="bibr">13</xref>].</p><p>In terms of genome structure and organization, LCVs are double-stranded DNA viruses of approximately 160 to 175 kb in size and encode similar open reading frames (ORFs) for lytic and latent proteins with near identical arrangement [<xref rid="B1-viruses-16-01923" ref-type="bibr">1</xref>,<xref rid="B14-viruses-16-01923" ref-type="bibr">14</xref>,<xref rid="B15-viruses-16-01923" ref-type="bibr">15</xref>,<xref rid="B16-viruses-16-01923" ref-type="bibr">16</xref>]. In addition to viral proteins, LCVs encode several regulatory non-coding RNAs, such as microRNAs (miRNAs), which are expressed throughout the viral life cycle and act to post-transcriptionally regulate gene expression [<xref rid="B17-viruses-16-01923" ref-type="bibr">17</xref>,<xref rid="B18-viruses-16-01923" ref-type="bibr">18</xref>,<xref rid="B19-viruses-16-01923" ref-type="bibr">19</xref>,<xref rid="B20-viruses-16-01923" ref-type="bibr">20</xref>]. While viral miRNA sequences are well documented for rhesus LCV, which infects rhesus macaques (<italic toggle="yes">Macaca mulatta</italic>), miRNAs expressed by other NHP LCVs are not fully annotated [<xref rid="B17-viruses-16-01923" ref-type="bibr">17</xref>,<xref rid="B18-viruses-16-01923" ref-type="bibr">18</xref>,<xref rid="B19-viruses-16-01923" ref-type="bibr">19</xref>,<xref rid="B20-viruses-16-01923" ref-type="bibr">20</xref>]. As NHPs represent a critical resource for biomedical research due to their close phylogeny to humans, there remains a continuing need to develop and expand molecular tools that support the evaluation of infectious diseases such as persistent gamma-herpesviruses in these models. </p><p>Thus, our overarching goals for this study were (i) to define the miRNAs encoded by LCVs which infect cynomolgus macaques and other NHP species, representing two of the three arms of the primate phylogeny, and (ii) to determine whether these small viral RNAs can be detected in circulation in vivo. Importantly, our data show that multiple cyLCV miRNAs are detected in plasma in a cynomolgus macaque with PTLD, highlighting the utility of viral miRNAs as potential diagnostic and/or prognostic biomarkers for LCV-associated disease.</p></sec><sec id="sec2-viruses-16-01923"><title>2. Materials and Methods</title><p><italic toggle="yes">Cell culture</italic>: B cell lines were maintained at 37 &#x000b0;C in a humidified atmosphere with 5% CO<sub>2</sub> in RPMI-1640 supplemented with 15% fetal bovine serum and 1% penicillin/streptomycin/L-glutamine. CyLCV-positive cyLCLs are derived by the spontaneous outgrowth of cyLCV-infected cells from PBMCs, as well as multiple lymph node (LN) tissues from Mauritian cynomolgus macaque (MCM) 35132, which developed PTLD following hematopoietic stem cell transplantation (HSCT) [<xref rid="B7-viruses-16-01923" ref-type="bibr">7</xref>,<xref rid="B12-viruses-16-01923" ref-type="bibr">12</xref>]. S594 cells from ATCC (CVCL-E151) are infected with CeHV12 and are originally derived from the spontaneous outgrowth of peripheral blood cells from a baboon [<xref rid="B21-viruses-16-01923" ref-type="bibr">21</xref>]. Rhesus LCL 309-98 cells are infected with rhesus LCV (rLCV) strain 8664 [<xref rid="B9-viruses-16-01923" ref-type="bibr">9</xref>]. EBV-positive Raji (CCL-86) and EBV-negative BJAB are both human BL cell lines. </p><p><italic toggle="yes">Viral miRNA sequencing and bioinformatics analysis</italic>: Total RNA was isolated from spontaneous cyLCLs established from PBMCs isolated from MCM 35132. A miRNA sequencing library was generated using the NEBNext small RNA kit (New England Biolabs, Ipswich, MA, USA), according to the manufacturer&#x02019;s protocol. Sequencing was performed on the Illumina HiSeq 2500 (Novogene, Sacramento, CA, USA). Reads were obtained in fastq format. Data were filtered to exclude short reads &#x0003c;16 nt and low-quality reads using FastQC and aligned to the cyLCV genome (Lymphocryptovirus Macaca/pfe-lcl-E3; NC_055142) using Bowtie2 [<xref rid="B22-viruses-16-01923" ref-type="bibr">22</xref>], allowing for up to two mismatches.</p><p>Total RNA was isolated from S594 cells using TRIzol (ThermoFisher Scientific, Waltham, MA, USA), according to the manufacturer&#x02019;s protocol, with minor modifications (95% ethanol wash). Small RNAs were enriched from the total RNA using the miRVana miRNA isolation kit (ThermoFisher Scientific, Waltham, MA, USA) and used to generate Illumina TruSeq small RNA sequencing libraries per the manufacturer&#x02019;s instructions. Sequencing (50 cycle, SE) was performed on the Illumina HiSeq 2000 platform at the OHSU MPSSR. Sequencing reads were obtained in fastq format, filtered using FastQC, and aligned to the <italic toggle="yes">Papio anubis</italic> genome assembly (Panu 3.0) using Bowtie2 [<xref rid="B22-viruses-16-01923" ref-type="bibr">22</xref>], allowing for up to two mismatches. Aligned reads were mapped to known primate pre-miRNA sequences annotated in miRBase v21 using scripts from the miRDeep2 pipeline [<xref rid="B23-viruses-16-01923" ref-type="bibr">23</xref>]. Remaining unmapped sequences were initially aligned to the EBV (NC_007605) and rhesus LCV (NC_006146) genomes and then the assembled CeHV12 BART region (see below) with up to two mismatches to identify potential viral miRNAs.</p><p><italic toggle="yes">DNA isolation, PCR amplicons, and sequence analysis of the CeHV12 BART region</italic>: Genomic DNA was isolated from S594 cells using DNAzol (ThermoFisher Scientific, Waltham, MA, USA), according to the manufacturer&#x02019;s protocol. Primers for the PCR amplification of the CeHV12 BART region and sequencing are listed in <xref rid="app1-viruses-16-01923" ref-type="app">Table S2</xref>. PCR products were amplified from S594 genomic DNA, purified by electrophoresis on 1% tris-acetate EDTA (TAE) agarose gels, and submitted for Sanger sequencing. The CeHV12 BART Cluster II region was subsequently assembled in Geneious Prime 2023.0.4 from sequenced PCR amplicons, obtaining approximately three-fold coverage. </p><p><italic toggle="yes">Prediction of Pan paniscus LCV1 and HVMA pre-miRNAs</italic>: To define Pan paniscus LCV1 pre-miRNAs, Pan paniscus isolate Ulindi viral contigs (AJFE01003225.1, AJFE01121077.1, AJFE01006050.1) with significant homology (based on BLAST alignments) to EBV BHRF1 and BART regions were aligned to known EBV and rLCV pre-miRNA sequences using the multiple sequence alignment Clustal Omega (<uri xlink:href="http://www.ebi.ac.uk/Tools/msa/clustalo/">http://www.ebi.ac.uk/Tools/msa/clustalo/</uri>) (last accessed on 19 November 2024). Pan paniscus LCV1 regions with extensive homology to LCV miRNA hairpins were extracted and folded with RNAfold (<uri xlink:href="http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi">http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi</uri>) (last accessed on 19 November 2024) and mFold [<xref rid="B24-viruses-16-01923" ref-type="bibr">24</xref>] to define candidate pre-miRNA hairpin structures. To determine HVMA pre-miRNAs, EBV and rLCV pre-miRNA sequences were aligned to the Macaca arctoides gammaherpesvirus 1 genome (MG471437.1, Macacine gammaherpesvirus 13) using Clustal Omega. Regions with extensive homology were extracted and folded with mFold [<xref rid="B24-viruses-16-01923" ref-type="bibr">24</xref>] to confirm hairpin structures.</p><p><italic toggle="yes">Plasma miRNA extraction and miRNA qRT-PCR</italic>: miRNAs were isolated from plasma samples as previously described [<xref rid="B25-viruses-16-01923" ref-type="bibr">25</xref>]. Briefly, miRNAs were extracted from plasma using the miRNeasy mini kit (Qiagen, Hilden, Germany) and eluted into nuclease-free water. To assay miRNA expression, total RNA was reverse-transcribed using miRNA-specific Taqman (ThermoFisher Scientific, Waltham, MA, USA) primers and miRNAs were detected using miRNA-specific Taqman probes and Taqman Universal PCR mastermix (ThermoFisher Scientific, Waltham, MA, USA). For the detection of miR-cyL-10-5p and miR-cyL-30-5p and the corresponding rLCV miRNAs, the EBV miRNA stem-loop primers and Taqman probes for miR-BART5 and miR-BART20 were used. For the detection of miR-cyL-2-5p, we used stem-loop primers that can amplify both rLCV miR-rL1-2-5p and EBV miR-BHRF1-2-5p and the distinct Taqman probes that are specific for either miR-cyL-2-5p/miR-rL1-2-5p or miR-BHRF1-2-5p. miRNA levels were normalized to miR-16. All PCR reactions were performed in technical replicates.</p><p><italic toggle="yes">Statistical analysis</italic>: Statistical analysis was performed in GraphPad Prism 10. Student&#x02019;s <italic toggle="yes">t</italic>-test was used to compare miRNA levels between plasma samples, and <italic toggle="yes">p</italic> values of &#x0003c;0.05 were considered significant.</p></sec><sec sec-type="results" id="sec3-viruses-16-01923"><title>3. Results</title><sec id="sec3dot1-viruses-16-01923"><title>3.1. Identification of Viral miRNAs Encoded by Cynomolgus Macaque Lymphocryptovirus (cyLCV) </title><p>The genome of cyLCV was first sequenced in 2016 [<xref rid="B15-viruses-16-01923" ref-type="bibr">15</xref>], and based on &#x0003e;96% sequence identity following pairwise alignment to the rLCV BHRF1 region, Kampershroer et al. reported four potential cyLCV homologs of the BHRF1 miRNAs. Interestingly, regions of the cyLCV genome with no predicted protein coding sequences, such as ~123&#x02013;133 kbp and ~149&#x02013;153 kbp, which flank cyLCV LF3 where other LCV BART miRNAs are known to be encoded, exhibited high levels of dissimilarity to rLCV [<xref rid="B15-viruses-16-01923" ref-type="bibr">15</xref>] and thus, no other cyLCV miRNAs were annotated at that time. Recently, we reported five new genome sequences for cyLCVs isolated from multiple MCM with PTLD or PTLD-like disease [<xref rid="B7-viruses-16-01923" ref-type="bibr">7</xref>]; these strains exhibited ~99.7% identity within their predicted BART-miRNA encoding regions. The pairwise alignments of these cyLCV isolates (PQ385619, PQ385620, PQ385621, PQ385622, PQ385623) to corresponding BART regions of the rhesus LCV genome revealed 57.9&#x02013;60.5% identity, with several smaller ~50&#x02013;70 nucleotide (nt) regions exhibiting &#x0003e;85% identity, suggesting that multiple BART viral miRNA homologs are indeed encoded by cyLCV.</p><p>To gain experimental evidence for cyLCV-encoded miRNAs, we analyzed the small RNA population in a cyLCV-infected B cell line (MCM 35132 cyLCLs) that spontaneously outgrew from PBMCs of a MCM presenting with PTLD [<xref rid="B7-viruses-16-01923" ref-type="bibr">7</xref>,<xref rid="B12-viruses-16-01923" ref-type="bibr">12</xref>]. A small RNA library was generated using the NEB Next kit and sequenced on the Illumina platform. While the total read counts were low (172,160 reads due to sample multiplexing), we observed 5116 reads that mapped directly to the cyLCV genome (<xref rid="viruses-16-01923-f001" ref-type="fig">Figure 1</xref>A). Comparable to previous LCV small RNA sequencing studies, we identified a few reads mapping to the cyLCV EBER regions; however, most viral hits occurred in the BHRF1 and BART homologous regions of the genome, consistent with small RNAs originating from these conserved viral miRNA loci. Following alignments to the cyLCV, rLCV, and EBV genomes, potential pre-miRNA folding structures were determined by mFold [<xref rid="B24-viruses-16-01923" ref-type="bibr">24</xref>]. The major cyLCV miRNA sequences with annotated 5&#x02032; and 3&#x02032; ends are listed in <xref rid="app1-viruses-16-01923" ref-type="app">Table S1</xref>. In total, we defined 34 distinct pre-miRNA hairpin structures for cyLCV, with direct experimental evidence for 28 of these pre-miRNAs (<xref rid="viruses-16-01923-f001" ref-type="fig">Figure 1</xref>B; <xref rid="app1-viruses-16-01923" ref-type="app">Table S1</xref>). </p><p>To obtain the further experimental evidence of cyLCV miRNAs, we extracted total RNA from additional cyLCLs that were independently derived from lymph node (LN) and tissues (axillary, inguinal, and mesenteric LN, spleen) collected from MCM 35132 at necropsy [<xref rid="B7-viruses-16-01923" ref-type="bibr">7</xref>,<xref rid="B12-viruses-16-01923" ref-type="bibr">12</xref>]. Using qRT-PCR, we tested the expression of three highly conserved viral miRNAs: homologs of EBV miR-BHRF1-2-5p (cyLCV miR-cyL-2-5p), EBV miR-BART5 (cyLCV miR-cyL-10-5p), and EBV miR-BART20 (cyLCV miR-cyL-30-5p), which all exhibit 100% homology within their seed regions (nucleotides two through eight) (<xref rid="viruses-16-01923-f001" ref-type="fig">Figure 1</xref>D). EBV-positive Raji cells and rLCV-positive rLCLs were included as controls. <xref rid="viruses-16-01923-f001" ref-type="fig">Figure 1</xref>C shows the expression level for each cyLCV miRNA in cyLCLs. Taken together, these data confirm the presence of cyLCV miRNAs and provide the first annotation of the small RNAs encoded by cyLCV. </p></sec><sec id="sec3dot2-viruses-16-01923"><title>3.2. Prediction of miRNAs Encoded by Bonobo Lymphocryptovirus (Pan paniscus LCV1)</title><p>In 2014, Aswad and Katzourakis reported novel sequences for Pan paniscus LCV1 following a query of primate genomes in the NCBI whole genome shotgun (WGS) database for herpesvirus-like sequences [<xref rid="B26-viruses-16-01923" ref-type="bibr">26</xref>]. Pan paniscus LCV1 naturally infects bonobos (<italic toggle="yes">Pan paniscus</italic>; also referred to as pygmy chimpanzees) and epidemiological studies show the virus is highly disseminated amongst wild bonobos [<xref rid="B27-viruses-16-01923" ref-type="bibr">27</xref>]. Notably, three of the reported viral contigs (AJFE01003225.1, AJFE01121077.1, and AJFE01006050.1) overlap the BHRF1 and BART miRNA encoding regions of EBV and other LCVs. To determine whether Pan paniscus LCV1 encodes miRNAs, we therefore aligned EBV, rLCV, and cyLCV pre-miRNA sequences to these three contigs initially using NCBI BLAST and subsequently, identified conserved pre-miRNAs through pairwise alignments in Clustal Omega. Putative Pan paniscus LCV1 miRNA precursors were extracted and folded with mfold [<xref rid="B24-viruses-16-01923" ref-type="bibr">24</xref>] to define potential hairpin structures (<xref rid="viruses-16-01923-f002" ref-type="fig">Figure 2</xref>). No BART Cluster II miRNAs could be determined for Pan paniscus LCV1 since the contig sequence AJFE01003225.1 ends within BART Cluster I. In total, we identified 12 conserved hairpins corresponding to homologs of all four BHRF1 miRNA precursors and eight BART Cluster I miRNA precursors. </p></sec><sec id="sec3dot3-viruses-16-01923"><title>3.3. Prediction of miRNAs Encoded by HVMA (Macacine Gammaherpesvirus 13)</title><p>The genome of an LCV isolate, HVMA, that naturally infects stump-tailed macaques (<italic toggle="yes">Macaca arctoides</italic>) was recently sequenced [<xref rid="B16-viruses-16-01923" ref-type="bibr">16</xref>]. To determine whether HVMA encodes viral miRNAs, we aligned the rLCV and cyLCV pre-miRNA hairpin sequences to the HVMA genome initially using NCBI BLAST and subsequently, identified conserved pre-miRNA sequences using Clustal Omega. Putative HVMA miRNA precursors were extracted and folded with mfold [<xref rid="B24-viruses-16-01923" ref-type="bibr">24</xref>] to define the hairpin structures (<xref rid="viruses-16-01923-f003" ref-type="fig">Figure 3</xref>). Comparable to rLCV, cyLCV, and Pan paniscus LCV1, the homologs of four BHRF1 miRNA precursors were present in the genome (<xref rid="viruses-16-01923-f003" ref-type="fig">Figure 3</xref>A). Moreover, we identified 31 putative pre-miRNA structures with homology to other LCV BART miRNAs, including miR-maL-35 which is encoded antisense to the BALF 3&#x02032;UTR akin to EBV miR-BART2. Predicted pre-miRNA structures for 5 of the 35 predicted HVMA miRNAs are shown in <xref rid="viruses-16-01923-f003" ref-type="fig">Figure 3</xref>B.</p></sec><sec id="sec3dot4-viruses-16-01923"><title>3.4. Experimental Identification of BHRF1 miRNA Homologs in CeV12-Infected S594 Cells</title><p>To experimentally define the miRNAs of CeHV12, also called Papiine gammaherpesvirus 1, we isolated and sequenced the small RNAs (&#x0003c;200 nt) expressed in S594 cells. S594 cells were originally derived from spleen tissue of a female baboon (<italic toggle="yes">Papio hamadryas</italic>) with lymphoreticular hyperplasia and are persistently infected with CeHV12 (Cercopithecine herpesvirus 12) [<xref rid="B21-viruses-16-01923" ref-type="bibr">21</xref>]. Small RNAs were extracted using the miRVana miRNA isolation kit, a cDNA library was prepared using the TruSeq small RNA kit, and miR-Seq (50-cycle, single end) was performed on the Illumina HiSeq2000. We obtained 15,971,595 total reads that were parsed, filtered, and aligned initially to the baboon (<italic toggle="yes">Papio anubis</italic>) genome (Panu3.0). To determine the cellular miRNAs, reads were aligned to all known primate miRNAs present in miRbase v21. Pre-miRNAs and candidates were additionally analyzed by miRDeep2 [<xref rid="B23-viruses-16-01923" ref-type="bibr">23</xref>], resulting in the detection of &#x0003e;250 cellular miRNAs, which accounted for 33% of the library (<xref rid="viruses-16-01923-f004" ref-type="fig">Figure 4</xref>A). The most abundant cellular miRNAs included homologs of human miR-148a, miR-92a, miR-146b, miR-21, miR-26a, and miR-191, which is consistent with a B cell miRNA profile. </p><p>In prior studies, four CeHV12 BHRF1 miRNA homologs were predicted [<xref rid="B17-viruses-16-01923" ref-type="bibr">17</xref>]. Based on the known locations of other LCV miRNA clusters, we predict that CeHV12 encodes at least twenty other distinct viral pre-miRNAs, beyond the four that are in the BHRF1 region. The remaining viral pre-miRNAs are presumably within the homologous BART region; however, the CeHV12 genome is not yet fully sequenced. To initially map miR-Seq reads of viral origin, we thus downloaded the 15 available CeV12 partial sequences from NCBI, including the H. papio FGARAT and BHRF1 regions (NCBI Accession # AF200364.1 and # AH009709.2). A total of ~4% of reads aligned to the BHRF1 locus, and spanned regions across the individual pre-miRNAs that were previously predicted [<xref rid="B17-viruses-16-01923" ref-type="bibr">17</xref>], providing the first experimental evidence for these viral miRNAs (<xref rid="viruses-16-01923-f004" ref-type="fig">Figure 4</xref>B). </p><p>Confirming previous predictions, CeHV12 miR-1 through miR-4 exhibit high sequence conservation to the EBV, rLCV, and cyLCV BHRF1 homologs (<xref rid="viruses-16-01923-f004" ref-type="fig">Figure 4</xref>C, <xref rid="app1-viruses-16-01923" ref-type="app">Table S1</xref>) [<xref rid="B17-viruses-16-01923" ref-type="bibr">17</xref>]. In human and rhesus macaque LCLs, EBV miR-BHRF1-2-3p and rLCV miR-rL1-2 are often the most abundant BHRF1 miRNAs expressed [<xref rid="B17-viruses-16-01923" ref-type="bibr">17</xref>,<xref rid="B18-viruses-16-01923" ref-type="bibr">18</xref>]. Based on miRNA read counts, we were surprised to find that CeHV12 miR-3-3p, a rLCV miR-rL1-17 and EBV miR-BHRF1-3 homolog, was the most abundant miRNA detected from this region and ranked fourth amongst all miRNAs detected in S594 cells (<xref rid="viruses-16-01923-f004" ref-type="fig">Figure 4</xref>B). Of note, both rLCV miR-rL1-17 and EBV miR-BHRF1-3 target the 3&#x02032;UTRs of the viral BZLF1 encoding an immediate early (IE) viral transactivator [<xref rid="B28-viruses-16-01923" ref-type="bibr">28</xref>]. While there are sequence differences between miR-rL1-17 and CeHV12 miR-3, it is plausible that CeHV12 miR-3 also regulates IE gene expression. Interestingly, both strands of CeHV12 miR-1 were detected, and we observed ten-times higher levels of the 3p strand compared to the 5p (<xref rid="app1-viruses-16-01923" ref-type="app">Table S3</xref>). This is directly opposite to what is normally seen for the EBV homolog, miR-BHRF1-1, for which the 5p arm is the dominant strand [<xref rid="B17-viruses-16-01923" ref-type="bibr">17</xref>]. As LCVs have species-specific tropism [<xref rid="B1-viruses-16-01923" ref-type="bibr">1</xref>], it is likely the nucleotide changes within these viral miRNA homologs have arisen to reflect the need for species-specific functions in terms of the target regulation. </p></sec><sec id="sec3dot5-viruses-16-01923"><title>3.5. Sequence Alignments Reveal Novel CeV12 BART Cluster II miRNAs</title><p>Using the genomic information from the homologous BART regions of EBV, rLCV, cyLCV, HVMA, and Pan paniscus LCV1, we next interrogated the S594 miR-Seq library for BART miRNA homologs. Partial homology was observed for sequences matching to multiple pre-miRNAs in EBV BART Cluster II and the homologous rLCV region&#x02014;specifically EBV miR-BART18, rLCV miR-rL1-11, EBV miR-BART12, EBV miR-BART20, and rLCV miR-rL1-32. We also identified homologs of EBV miR-BART1, miR-BART5, and miR-BART15 in BART Cluster I (<xref rid="viruses-16-01923-f005" ref-type="fig">Figure 5</xref>A; <xref rid="app1-viruses-16-01923" ref-type="app">Table S3</xref>). Based on the five potential CeHV12 miRNAs with homology to EBV BART Cluster II, we designed several PCR primers to amplify this miRNA-encoding region of the CeHV12 genome (<xref rid="app1-viruses-16-01923" ref-type="app">Table S2</xref>). Primer combinations were selected based on their predicted, evolutionarily conserved binding positions and used to generate PCR amplicons for Sanger sequencing. The sizes of PCR products are shown in <xref rid="viruses-16-01923-f005" ref-type="fig">Figure 5</xref>A. We were unable to obtain PCR products using the B1/B5 primer pair, and thus, no BART Cluster I miRNA precursors could be determined. Amplicons were gel purified, sequenced, and analyzed using Geneious Prime to compile the CeHV12 BART Cluster II region. This initial round of sequencing provided at least three-fold sequence coverage. Additional PCR amplicons were generated following the first round of sequencing to obtain a near-complete sequence of the CeHV12 BART Cluster II region. </p><p>S594 miR-Seq reads were subsequently aligned to the CeHV12 BART Cluster II region, revealing 12 areas with substantial numbers of mapped reads (<xref rid="viruses-16-01923-f005" ref-type="fig">Figure 5</xref>B). These 12 regions were extracted and folded in mfold [<xref rid="B24-viruses-16-01923" ref-type="bibr">24</xref>] to identify miRNA hairpin structures (<xref rid="viruses-16-01923-f005" ref-type="fig">Figure 5</xref>C). A total of 22 mature CeHV12 BART miRNAs arising from the 12 pre-miRNAs were defined. <xref rid="app1-viruses-16-01923" ref-type="app">Table S3</xref> lists the major isoforms of the 16 viral miRNAs detected in S594 cells. While no precursor structures are available for any CeHV12 miRNAs that arise from Cluster I, we have also included sequences for three putative viral miRNAs (miR-17, -18, -19) based on their alignments to EBV miR-BART1, miR-BART5 (rLCV miR-rL1-8), and miR-BART15 (rLCV miR-rL1-7) (<xref rid="app1-viruses-16-01923" ref-type="app">Table S3</xref>). Collectively, this analysis identified 19 CeHV12-encoded pre-miRNAs and defined the distinct 5&#x02032; ends for these small RNA molecules.</p></sec><sec id="sec3dot6-viruses-16-01923"><title>3.6. Circulating cyLCV miRNAs Are Detectable in MCM with PTLD</title><p>Viral miRNAs have significant promise as diagnostic biomarkers for viral infections and as prognostic biomarkers of viral pathogenesis [<xref rid="B29-viruses-16-01923" ref-type="bibr">29</xref>]. Moreover, there is substantial interest in developing non-invasive miRNA-based biomarkers for disease as these RNA molecules are stable in liquid biopsies such as plasma. Using qRT-PCR assays, we tested cyLCV miRNA expression in cell-free plasma samples from MCM 35132, a HSCT recipient that developed aggressive cyLCV-associated PTLD [<xref rid="B7-viruses-16-01923" ref-type="bibr">7</xref>,<xref rid="B12-viruses-16-01923" ref-type="bibr">12</xref>]. Plasma samples from MCM 35133, the corresponding healthy HSCT donor, were tested in parallel. CyLCV miRNAs were strongly detected at both 40 and 50 days post HSCT in MCM 35132, with significant increases in miR-cyL-2 and miR-cyL-10 between day 40 and 50 (<xref rid="viruses-16-01923-f006" ref-type="fig">Figure 6</xref>A), coinciding with the clinical detection of PTLD. Strikingly, circulating miR-cyL-30 in plasma samples at days 40 and 50 was quite elevated as levels were similar to the cell-associated miR-cyL-30 levels detected in cyLCLs (<xref rid="viruses-16-01923-f006" ref-type="fig">Figure 6</xref>A). Low levels of the cyLCV miRNAs were detected in MCM 35132 prior to HSCT&#x02014;even at 250 days prior&#x02014;which indicates pre-existing cyLCV infection (<xref rid="viruses-16-01923-f006" ref-type="fig">Figure 6</xref>A) and is consistent with the previously reported low level of cell-free cyLCV DNA detected in this macaque at day -20 prior to HSCT [<xref rid="B12-viruses-16-01923" ref-type="bibr">12</xref>]. No cyLCV miRNAs were detected in plasma samples from the HSCT donor, MCM 35133 (<xref rid="viruses-16-01923-f006" ref-type="fig">Figure 6</xref>B). Such observations suggest that the cyLCV-associated small RNA signature in MCM 35132 likely arose due to the reactivation of the pre-existing cyLCV infection in response to HSCT. Given the abundant level of miR-cyL-30 (homolog of EBV miR-BART20) found in circulation, we anticipate this viral miRNA to be a potential diagnostic marker of cyLCV-associated PTLD and viral pathogenesis in future studies with MCM. </p></sec></sec><sec sec-type="discussion" id="sec4-viruses-16-01923"><title>4. Discussion</title><p>In this study, we used small RNA-sequencing and in silico sequence alignments to identify conserved viral miRNAs encoded by four different simian LCVs that naturally infect Old World monkeys and hominoids. Importantly, we provide direct experimental support for and document the exact 5&#x02032; ends of viral miRNAs encoded by two of these LCVs: cyLCV that infects cynomolgus macaques and CeHV12 that infects baboons. As the 5&#x02032; seed sequence of a mature miRNA, which minimally consists of nucleotides two through seven, is a fundamental feature for miRNA function and essential for canonical base pairing with target messenger RNAs [<xref rid="B30-viruses-16-01923" ref-type="bibr">30</xref>], the precise annotation of the 5&#x02032; end provides key insight into the potential regulatory capabilities for these viral miRNAs.</p><p>LCVs exhibit species-specific tropism [<xref rid="B1-viruses-16-01923" ref-type="bibr">1</xref>], which presumably arose during co-evolution with their individual primate hosts. From fossil record evidence, the divergence of cercopithecoids (<italic toggle="yes">Papio</italic>, <italic toggle="yes">Macaca</italic>) and hominoids (<italic toggle="yes">Homo</italic>, <italic toggle="yes">Pan</italic>) is estimated to have occurred ~25 million years ago (25 MYA) while divergence of <italic toggle="yes">Papio</italic> and <italic toggle="yes">Macaca</italic> is estimated at 10&#x02013;12 MYA [<xref rid="B31-viruses-16-01923" ref-type="bibr">31</xref>,<xref rid="B32-viruses-16-01923" ref-type="bibr">32</xref>]. Interestingly, based on the phylogenetic analysis of the viral DNA polymerase genes (homologs of EBV BALF5) from &#x0003e;45 simian LCVs, two main lineages of LCVs infecting Old World monkeys were proposed [<xref rid="B33-viruses-16-01923" ref-type="bibr">33</xref>,<xref rid="B34-viruses-16-01923" ref-type="bibr">34</xref>]. Most notably, the divergence of EBV and other LCVs that infect hominids and LCVs that infect cercopithecoids was estimated at 12 MYA [<xref rid="B34-viruses-16-01923" ref-type="bibr">34</xref>]. As such, at the genetic level, LCVs are thought to be much closer in evolutionary time compared to their respective host species.</p><p>While LCVs are thought to have circulated amongst primates and subsequently co-evolved with their respective host species well after the divergence of hominids and macaques, these viruses exhibit synteny in their genome organization and significant sequence homology has been documented in their protein coding genes [<xref rid="B14-viruses-16-01923" ref-type="bibr">14</xref>,<xref rid="B15-viruses-16-01923" ref-type="bibr">15</xref>,<xref rid="B16-viruses-16-01923" ref-type="bibr">16</xref>,<xref rid="B26-viruses-16-01923" ref-type="bibr">26</xref>]. Taking advantage of these genetic attributes enabled us to compare reference viral genomes and published sequence contigs to predict the ~60 nt pre-miRNAs for two other simian LCVs that infect stump-tailed macaques and bonobos. As there is no precise evolutionary model for viral miRNA-encoding genes, we relied on the structural hallmarks of miRNA precursors and sequence identity in the mature miRNA seed regions to define these additional LCV pre-miRNAs. Intriguingly, the multiple sequence alignment of the LCV BART Cluster I regions from EBV, rLCV, cyLCV, HVMA, and Pan paniscus LCV1 revealed only 48.3% identity overall; however, higher sequence homology (&#x0003e;80&#x02013;88% identity) is observed within the ~60 nt pre-miRNAs themselves, indicating that these small RNA-encoding regions are maintained through ongoing selective pressure. Only minor differences in the miRNA seed regions (nt 2&#x02013;8) are observed for most NHP LCV BART miRNAs, which likely arose due to species-specific tropisms for these viruses.</p><p>Sequence variations in the BART Cluster II region have been reported for EBV type 2 strains, including several strains circulating in Papa New Guinea [<xref rid="B35-viruses-16-01923" ref-type="bibr">35</xref>]. Most noteworthy is a ~71&#x02013;73 nt expansion between EBV miR-BART21 and miR-BART18 [<xref rid="B35-viruses-16-01923" ref-type="bibr">35</xref>] that is not observed in EBV type 1 strains and potentially encodes an RNA with a hairpin-like structure. Comparing the BART Cluster II from EBV type 2 (NC_009334) to the BART Cluster II regions of rLCV, cyLCV, and HVMA, we observe homologs of both EBV miR-BART21 and miR-BART18 in the NHP LCVs. However, between the miR-BART21 and miR-BART18 homologs is an additional miRNA; in rLCV, this miRNA is miR-rL1-10 [<xref rid="B17-viruses-16-01923" ref-type="bibr">17</xref>,<xref rid="B18-viruses-16-01923" ref-type="bibr">18</xref>,<xref rid="B20-viruses-16-01923" ref-type="bibr">20</xref>], and in cyLCV, this miRNA is miR-cyL-17. While future studies will be needed to confirm whether the documented ~71&#x02013;73 nt expansion in EBV type 2 indeed encodes a Drosha substrate that can be processed into functional miRNA(s), it is quite plausible this region represents a positional homolog of the rLCV miR-rL1-10 precursor.</p><p>In summary, we successfully annotated &#x0003e;95 viral miRNAs encoded by simian LCVs that naturally infect hominoids and Old-World monkeys. These results provide a molecular resource that enables the development of sequence-specific reagents to track LCV gene expression in vivo. To our knowledge, this is the first study that reports experimental evidence of cyLCV and CeHV12 miRNAs and, notably, demonstrates that cyLCV miRNAs, such as miR-cyL-30, have utility as circulating biomarkers of viral infection in PTLD. Further efforts to sequence additional LCV genomes and miRNAs can strengthen these initial observations and provide tools for new diagnostics of LCV-associated diseases.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank the OHSU MPSSR for support with miRNA sequencing.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-viruses-16-01923"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/v16121923/s1">https://www.mdpi.com/article/10.3390/v16121923/s1</uri>. Table S1: cyLCV miRNA sequences; Table S2: Primers used for CeHV12 amplicon sequencing; Table S3: CeHV12 miRNA sequences.</p><supplementary-material id="viruses-16-01923-s001" position="float" content-type="local-data"><media xlink:href="viruses-16-01923-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, Y.C. and R.L.S.; methodology, Y.C. and D.N.F.; investigation and data curation, Y.C., D.N.F., H.L.W. and R.L.S.; writing&#x02014;original draft preparation, R.L.S.; writing&#x02014;review and editing, Y.C., D.N.F., H.L.W., J.B.S. and R.L.S.; supervision, J.B.S. and R.L.S.; project administration, R.L.S.; funding acquisition, J.B.S. and R.L.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>miRNA sequencing datasets can be accessed through the NCBI SRA database under BioProject ID PRJNA1186720.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-16-01923"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Muhe</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
</person-group><article-title>Non-human Primate Lymphocryptoviruses: Past, Present, and Future</article-title><source>Curr. Top. Microbiol. Immunol.</source><year>2015</year><volume>391</volume><fpage>385</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1007/978-3-319-22834-1_13</pub-id><pub-id pub-id-type="pmid">26428382</pub-id>
</element-citation></ref><ref id="B2-viruses-16-01923"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Young</surname><given-names>L.S.</given-names></name>
<name><surname>Yap</surname><given-names>L.F.</given-names></name>
<name><surname>Murray</surname><given-names>P.G.</given-names></name>
</person-group><article-title>Epstein-Barr virus: More than 50 years old and still providing surprises</article-title><source>Nat. Rev. Cancer</source><year>2016</year><volume>16</volume><fpage>789</fpage><lpage>802</lpage><pub-id pub-id-type="doi">10.1038/nrc.2016.92</pub-id><pub-id pub-id-type="pmid">27687982</pub-id>
</element-citation></ref><ref id="B3-viruses-16-01923"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Farrell</surname><given-names>P.J.</given-names></name>
</person-group><article-title>Epstein-Barr Virus and Cancer</article-title><source>Annu. Rev. Pathol.</source><year>2019</year><volume>14</volume><fpage>29</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathmechdis-012418-013023</pub-id><pub-id pub-id-type="pmid">30125149</pub-id>
</element-citation></ref><ref id="B4-viruses-16-01923"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Escalante</surname><given-names>G.M.</given-names></name>
<name><surname>Mutsvunguma</surname><given-names>L.Z.</given-names></name>
<name><surname>Muniraju</surname><given-names>M.</given-names></name>
<name><surname>Rodriguez</surname><given-names>E.</given-names></name>
<name><surname>Ogembo</surname><given-names>J.G.</given-names></name>
</person-group><article-title>Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>867918</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.867918</pub-id><pub-id pub-id-type="pmid">35493498</pub-id>
</element-citation></ref><ref id="B5-viruses-16-01923"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fujiwara</surname><given-names>S.</given-names></name>
<name><surname>Nakamura</surname><given-names>H.</given-names></name>
</person-group><article-title>Animal Models for Gammaherpesvirus Infections: Recent Development in the Analysis of Virus-Induced Pathogenesis</article-title><source>Pathogens</source><year>2020</year><volume>9</volume><elocation-id>116</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens9020116</pub-id><pub-id pub-id-type="pmid">32059472</pub-id>
</element-citation></ref><ref id="B6-viruses-16-01923"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moghaddam</surname><given-names>A.</given-names></name>
<name><surname>Rosenzweig</surname><given-names>M.</given-names></name>
<name><surname>Lee-Parritz</surname><given-names>D.</given-names></name>
<name><surname>Annis</surname><given-names>B.</given-names></name>
<name><surname>Johnson</surname><given-names>R.P.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
</person-group><article-title>An animal model for acute and persistent Epstein-Barr virus infection</article-title><source>Science</source><year>1997</year><volume>276</volume><fpage>2030</fpage><lpage>2033</lpage><pub-id pub-id-type="doi">10.1126/science.276.5321.2030</pub-id><pub-id pub-id-type="pmid">9197263</pub-id>
</element-citation></ref><ref id="B7-viruses-16-01923"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>H.L.</given-names></name>
<name><surname>Weber</surname><given-names>W.C.</given-names></name>
<name><surname>Waytashek</surname><given-names>C.M.</given-names></name>
<name><surname>Boyle</surname><given-names>C.D.</given-names></name>
<name><surname>Reed</surname><given-names>J.S.</given-names></name>
<name><surname>Bateman</surname><given-names>K.B.</given-names></name>
<name><surname>Fisher</surname><given-names>H.K.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Armantrout</surname><given-names>K.</given-names></name>
<name><surname>Swanson</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>A model of lymphocryptovirus-associated post-transplant lymphoproliferative disorder in immunosuppressed Mauritian cynomolgus macaques</article-title><source>PLoS Pathog.</source><year>2024</year><volume>20</volume><elocation-id>e1012644</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1012644</pub-id><pub-id pub-id-type="pmid">39527641</pub-id>
</element-citation></ref><ref id="B8-viruses-16-01923"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Estes</surname><given-names>J.D.</given-names></name>
<name><surname>Wong</surname><given-names>S.W.</given-names></name>
<name><surname>Brenchley</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Nonhuman primate models of human viral infections</article-title><source>Nat. Rev. Immunol.</source><year>2018</year><volume>18</volume><fpage>390</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1038/s41577-018-0005-7</pub-id><pub-id pub-id-type="pmid">29556017</pub-id>
</element-citation></ref><ref id="B9-viruses-16-01923"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rivailler</surname><given-names>P.</given-names></name>
<name><surname>Carville</surname><given-names>A.</given-names></name>
<name><surname>Kaur</surname><given-names>A.</given-names></name>
<name><surname>Rao</surname><given-names>P.</given-names></name>
<name><surname>Quink</surname><given-names>C.</given-names></name>
<name><surname>Kutok</surname><given-names>J.L.</given-names></name>
<name><surname>Westmoreland</surname><given-names>S.</given-names></name>
<name><surname>Klumpp</surname><given-names>S.</given-names></name>
<name><surname>Simon</surname><given-names>M.</given-names></name>
<name><surname>Aster</surname><given-names>J.C.</given-names></name>
<etal/>
</person-group><article-title>Experimental rhesus lymphocryptovirus infection in immunosuppressed macaques: An animal model for Epstein-Barr virus pathogenesis in the immunosuppressed host</article-title><source>Blood</source><year>2004</year><volume>104</volume><fpage>1482</fpage><lpage>1489</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-01-0342</pub-id><pub-id pub-id-type="pmid">15150077</pub-id>
</element-citation></ref><ref id="B10-viruses-16-01923"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Muhe</surname><given-names>J.</given-names></name>
<name><surname>Aye</surname><given-names>P.P.</given-names></name>
<name><surname>Quink</surname><given-names>C.</given-names></name>
<name><surname>Eng</surname><given-names>J.Y.</given-names></name>
<name><surname>Engelman</surname><given-names>K.</given-names></name>
<name><surname>Reimann</surname><given-names>K.A.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
</person-group><article-title>Neutralizing antibodies against Epstein-Barr virus infection of B cells can protect from oral viral challenge in the rhesus macaque animal model</article-title><source>Cell Rep. Med.</source><year>2021</year><volume>2</volume><fpage>100352</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2021.100352</pub-id><pub-id pub-id-type="pmid">34337567</pub-id>
</element-citation></ref><ref id="B11-viruses-16-01923"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Edwards</surname><given-names>K.R.</given-names></name>
<name><surname>Schmidt</surname><given-names>K.</given-names></name>
<name><surname>Homad</surname><given-names>L.J.</given-names></name>
<name><surname>Kher</surname><given-names>G.M.</given-names></name>
<name><surname>Xu</surname><given-names>G.</given-names></name>
<name><surname>Rodrigues</surname><given-names>K.A.</given-names></name>
<name><surname>Ben-Akiva</surname><given-names>E.</given-names></name>
<name><surname>Abbott</surname><given-names>J.</given-names></name>
<name><surname>Prlic</surname><given-names>M.</given-names></name>
<name><surname>Newell</surname><given-names>E.W.</given-names></name>
<etal/>
</person-group><article-title>Vaccination with nanoparticles displaying gH/gL from Epstein-Barr virus elicits limited cross-protection against rhesus lymphocryptovirus</article-title><source>Cell Rep. Med.</source><year>2024</year><volume>5</volume><fpage>101587</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2024.101587</pub-id><pub-id pub-id-type="pmid">38781964</pub-id>
</element-citation></ref><ref id="B12-viruses-16-01923"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>H.L.</given-names></name>
<name><surname>Weber</surname><given-names>W.C.</given-names></name>
<name><surname>Shriver-Munsch</surname><given-names>C.</given-names></name>
<name><surname>Swanson</surname><given-names>T.</given-names></name>
<name><surname>Northrup</surname><given-names>M.</given-names></name>
<name><surname>Price</surname><given-names>H.</given-names></name>
<name><surname>Armantrout</surname><given-names>K.</given-names></name>
<name><surname>Robertson-LeVay</surname><given-names>M.</given-names></name>
<name><surname>Reed</surname><given-names>J.S.</given-names></name>
<name><surname>Bateman</surname><given-names>K.B.</given-names></name>
<etal/>
</person-group><article-title>Viral opportunistic infections in Mauritian cynomolgus macaques undergoing allogeneic stem cell transplantation mirror human transplant infectious disease complications</article-title><source>Xenotransplantation</source><year>2020</year><volume>27</volume><fpage>e12578</fpage><pub-id pub-id-type="doi">10.1111/xen.12578</pub-id><pub-id pub-id-type="pmid">31930750</pub-id>
</element-citation></ref><ref id="B13-viruses-16-01923"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marshall</surname><given-names>V.A.</given-names></name>
<name><surname>Labo</surname><given-names>N.</given-names></name>
<name><surname>Hao</surname><given-names>X.P.</given-names></name>
<name><surname>Holdridge</surname><given-names>B.</given-names></name>
<name><surname>Thompson</surname><given-names>M.</given-names></name>
<name><surname>Miley</surname><given-names>W.</given-names></name>
<name><surname>Brands</surname><given-names>C.</given-names></name>
<name><surname>Coalter</surname><given-names>V.</given-names></name>
<name><surname>Kiser</surname><given-names>R.</given-names></name>
<name><surname>Anver</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Gammaherpesvirus infection and malignant disease in rhesus macaques experimentally infected with SIV or SHIV</article-title><source>PLoS Pathog.</source><year>2018</year><volume>14</volume><elocation-id>e1007130</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1007130</pub-id><pub-id pub-id-type="pmid">30001436</pub-id>
</element-citation></ref><ref id="B14-viruses-16-01923"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rivailler</surname><given-names>P.</given-names></name>
<name><surname>Jiang</surname><given-names>H.</given-names></name>
<name><surname>Cho</surname><given-names>Y.G.</given-names></name>
<name><surname>Quink</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
</person-group><article-title>Complete nucleotide sequence of the rhesus lymphocryptovirus: Genetic validation for an Epstein-Barr virus animal model</article-title><source>J. Virol.</source><year>2002</year><volume>76</volume><fpage>421</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1128/JVI.76.1.421-426.2002</pub-id><pub-id pub-id-type="pmid">11739708</pub-id>
</element-citation></ref><ref id="B15-viruses-16-01923"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kamperschroer</surname><given-names>C.</given-names></name>
<name><surname>Gosink</surname><given-names>M.M.</given-names></name>
<name><surname>Kumpf</surname><given-names>S.W.</given-names></name>
<name><surname>O&#x02019;Donnell</surname><given-names>L.M.</given-names></name>
<name><surname>Tartaro</surname><given-names>K.R.</given-names></name>
</person-group><article-title>The genomic sequence of lymphocryptovirus from cynomolgus macaque</article-title><source>Virology</source><year>2016</year><volume>488</volume><fpage>28</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2015.10.025</pub-id><pub-id pub-id-type="pmid">26590795</pub-id>
</element-citation></ref><ref id="B16-viruses-16-01923"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krumbholz</surname><given-names>A.</given-names></name>
<name><surname>Roempke</surname><given-names>J.</given-names></name>
<name><surname>Liehr</surname><given-names>T.</given-names></name>
<name><surname>Groth</surname><given-names>M.</given-names></name>
<name><surname>Meerbach</surname><given-names>A.</given-names></name>
<name><surname>Schacke</surname><given-names>M.</given-names></name>
<name><surname>Maschkowitz</surname><given-names>G.</given-names></name>
<name><surname>Fickenscher</surname><given-names>H.</given-names></name>
<name><surname>Klapper</surname><given-names>W.</given-names></name>
<name><surname>Sauerbrei</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Macaca arctoides gammaherpesvirus 1 (strain herpesvirus Macaca arctoides): Virus sequence, phylogeny and characterisation of virus-transformed macaque and rabbit cell lines</article-title><source>Med. Microbiol. Immunol.</source><year>2019</year><volume>208</volume><fpage>109</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1007/s00430-018-0565-y</pub-id><pub-id pub-id-type="pmid">30291474</pub-id>
</element-citation></ref><ref id="B17-viruses-16-01923"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Skalsky</surname><given-names>R.L.</given-names></name>
<name><surname>Kang</surname><given-names>D.</given-names></name>
<name><surname>Linnstaedt</surname><given-names>S.D.</given-names></name>
<name><surname>Cullen</surname><given-names>B.R.</given-names></name>
</person-group><article-title>Evolutionary conservation of primate lymphocryptovirus microRNA targets</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>1617</fpage><lpage>1635</lpage><pub-id pub-id-type="doi">10.1128/JVI.02071-13</pub-id><pub-id pub-id-type="pmid">24257599</pub-id>
</element-citation></ref><ref id="B18-viruses-16-01923"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Riley</surname><given-names>K.J.</given-names></name>
<name><surname>Rabinowitz</surname><given-names>G.S.</given-names></name>
<name><surname>Steitz</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Comprehensive analysis of Rhesus lymphocryptovirus microRNA expression</article-title><source>J. Virol.</source><year>2010</year><volume>84</volume><fpage>5148</fpage><lpage>5157</lpage><pub-id pub-id-type="doi">10.1128/JVI.00110-10</pub-id><pub-id pub-id-type="pmid">20219930</pub-id>
</element-citation></ref><ref id="B19-viruses-16-01923"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Walz</surname><given-names>N.</given-names></name>
<name><surname>Christalla</surname><given-names>T.</given-names></name>
<name><surname>Tessmer</surname><given-names>U.</given-names></name>
<name><surname>Grundhoff</surname><given-names>A.</given-names></name>
</person-group><article-title>A global analysis of evolutionary conservation among known and predicted gammaherpesvirus microRNAs</article-title><source>J. Virol.</source><year>2010</year><volume>84</volume><fpage>716</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1128/JVI.01302-09</pub-id><pub-id pub-id-type="pmid">19889779</pub-id>
</element-citation></ref><ref id="B20-viruses-16-01923"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cai</surname><given-names>X.</given-names></name>
<name><surname>Schafer</surname><given-names>A.</given-names></name>
<name><surname>Lu</surname><given-names>S.</given-names></name>
<name><surname>Bilello</surname><given-names>J.P.</given-names></name>
<name><surname>Desrosiers</surname><given-names>R.C.</given-names></name>
<name><surname>Edwards</surname><given-names>R.</given-names></name>
<name><surname>Raab-Traub</surname><given-names>N.</given-names></name>
<name><surname>Cullen</surname><given-names>B.R.</given-names></name>
</person-group><article-title>Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed</article-title><source>PLoS Pathog.</source><year>2006</year><volume>2</volume><elocation-id>e23</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.0020023</pub-id><pub-id pub-id-type="pmid">16557291</pub-id>
</element-citation></ref><ref id="B21-viruses-16-01923"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rabin</surname><given-names>H.</given-names></name>
<name><surname>Neubauer</surname><given-names>R.H.</given-names></name>
<name><surname>Hopkins</surname><given-names>R.F.</given-names><suffix>3rd</suffix></name>
<name><surname>Dzhikidze</surname><given-names>E.K.</given-names></name>
<name><surname>Shevtsova</surname><given-names>Z.V.</given-names></name>
<name><surname>Lapin</surname><given-names>B.A.</given-names></name>
</person-group><article-title>Transforming activity and antigenicity of an Epstein-Barr-like virus from lymphoblastoid cell lines of baboons with lymphoid disease</article-title><source>Intervirology</source><year>1977</year><volume>8</volume><fpage>240</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1159/000148899</pub-id><pub-id pub-id-type="pmid">194867</pub-id>
</element-citation></ref><ref id="B22-viruses-16-01923"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Langmead</surname><given-names>B.</given-names></name>
<name><surname>Salzberg</surname><given-names>S.L.</given-names></name>
</person-group><article-title>Fast gapped-read alignment with Bowtie 2</article-title><source>Nat. Methods</source><year>2012</year><volume>9</volume><fpage>357</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1923</pub-id><pub-id pub-id-type="pmid">22388286</pub-id>
</element-citation></ref><ref id="B23-viruses-16-01923"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Friedlander</surname><given-names>M.R.</given-names></name>
<name><surname>Mackowiak</surname><given-names>S.D.</given-names></name>
<name><surname>Li</surname><given-names>N.</given-names></name>
<name><surname>Chen</surname><given-names>W.</given-names></name>
<name><surname>Rajewsky</surname><given-names>N.</given-names></name>
</person-group><article-title>miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades</article-title><source>Nucleic Acids Res.</source><year>2012</year><volume>40</volume><fpage>37</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1093/nar/gkr688</pub-id><pub-id pub-id-type="pmid">21911355</pub-id>
</element-citation></ref><ref id="B24-viruses-16-01923"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zuker</surname><given-names>M.</given-names></name>
</person-group><article-title>Mfold web server for nucleic acid folding and hybridization prediction</article-title><source>Nucleic Acids Res.</source><year>2003</year><volume>31</volume><fpage>3406</fpage><lpage>3415</lpage><pub-id pub-id-type="doi">10.1093/nar/gkg595</pub-id><pub-id pub-id-type="pmid">12824337</pub-id>
</element-citation></ref><ref id="B25-viruses-16-01923"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Varco-Merth</surname><given-names>B.D.</given-names></name>
<name><surname>Brantley</surname><given-names>W.</given-names></name>
<name><surname>Marenco</surname><given-names>A.</given-names></name>
<name><surname>Duell</surname><given-names>D.D.</given-names></name>
<name><surname>Fachko</surname><given-names>D.N.</given-names></name>
<name><surname>Richardson</surname><given-names>B.</given-names></name>
<name><surname>Busman-Sahay</surname><given-names>K.</given-names></name>
<name><surname>Shao</surname><given-names>D.</given-names></name>
<name><surname>Flores</surname><given-names>W.</given-names></name>
<name><surname>Engelman</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Rapamycin limits CD4+ T cell proliferation in simian immunodeficiency virus-infected rhesus macaques on antiretroviral therapy</article-title><source>J. Clin. Investig.</source><year>2022</year><volume>132</volume><fpage>e156063</fpage><pub-id pub-id-type="doi">10.1172/JCI156063</pub-id><pub-id pub-id-type="pmid">35316218</pub-id>
</element-citation></ref><ref id="B26-viruses-16-01923"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aswad</surname><given-names>A.</given-names></name>
<name><surname>Katzourakis</surname><given-names>A.</given-names></name>
</person-group><article-title>The first endogenous herpesvirus, identified in the tarsier genome, and novel sequences from primate rhadinoviruses and lymphocryptoviruses</article-title><source>PLoS Genet.</source><year>2014</year><volume>10</volume><elocation-id>e1004332</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1004332</pub-id><pub-id pub-id-type="pmid">24945689</pub-id>
</element-citation></ref><ref id="B27-viruses-16-01923"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoshida</surname><given-names>T.</given-names></name>
<name><surname>Takemoto</surname><given-names>H.</given-names></name>
<name><surname>Sakamaki</surname><given-names>T.</given-names></name>
<name><surname>Tokuyama</surname><given-names>N.</given-names></name>
<name><surname>Hart</surname><given-names>J.</given-names></name>
<name><surname>Hart</surname><given-names>T.</given-names></name>
<name><surname>Dupain</surname><given-names>J.</given-names></name>
<name><surname>Cobden</surname><given-names>A.</given-names></name>
<name><surname>Mulavwa</surname><given-names>M.</given-names></name>
<name><surname>Kawamoto</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Epidemiological Surveillance of Lymphocryptovirus Infection in Wild Bonobos</article-title><source>Front. Microbiol.</source><year>2016</year><volume>7</volume><elocation-id>1262</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2016.01262</pub-id><pub-id pub-id-type="pmid">27570523</pub-id>
</element-citation></ref><ref id="B28-viruses-16-01923"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fachko</surname><given-names>D.N.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Skalsky</surname><given-names>R.L.</given-names></name>
</person-group><article-title>Epstein-Barr Virus miR-BHRF1-3 Targets the BZLF1 3&#x02032;UTR and Regulates the Lytic Cycle</article-title><source>J. Virol.</source><year>2022</year><volume>96</volume><fpage>e0149521</fpage><pub-id pub-id-type="doi">10.1128/jvi.01495-21</pub-id><pub-id pub-id-type="pmid">34878852</pub-id>
</element-citation></ref><ref id="B29-viruses-16-01923"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Skalsky</surname><given-names>R.L.</given-names></name>
</person-group><article-title>MicroRNA-mediated control of Epstein-Barr virus infection and potential diagnostic and therapeutic implications</article-title><source>Curr. Opin. Virol.</source><year>2022</year><volume>56</volume><fpage>101272</fpage><pub-id pub-id-type="doi">10.1016/j.coviro.2022.101272</pub-id><pub-id pub-id-type="pmid">36242893</pub-id>
</element-citation></ref><ref id="B30-viruses-16-01923"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lewis</surname><given-names>B.P.</given-names></name>
<name><surname>Burge</surname><given-names>C.B.</given-names></name>
<name><surname>Bartel</surname><given-names>D.P.</given-names></name>
</person-group><article-title>Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets</article-title><source>Cell</source><year>2005</year><volume>120</volume><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2004.12.035</pub-id><pub-id pub-id-type="pmid">15652477</pub-id>
</element-citation></ref><ref id="B31-viruses-16-01923"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schrago</surname><given-names>C.G.</given-names></name>
<name><surname>Russo</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Timing the origin of New World monkeys</article-title><source>Mol. Biol. Evol.</source><year>2003</year><volume>20</volume><fpage>1620</fpage><lpage>1625</lpage><pub-id pub-id-type="doi">10.1093/molbev/msg172</pub-id><pub-id pub-id-type="pmid">12832653</pub-id>
</element-citation></ref><ref id="B32-viruses-16-01923"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stewart</surname><given-names>C.B.</given-names></name>
<name><surname>Disotell</surname><given-names>T.R.</given-names></name>
</person-group><article-title>Primate evolution&#x02014;In and out of Africa</article-title><source>Curr. Biol.</source><year>1998</year><volume>8</volume><fpage>R582</fpage><lpage>R588</lpage><pub-id pub-id-type="doi">10.1016/S0960-9822(07)00367-3</pub-id><pub-id pub-id-type="pmid">9707399</pub-id>
</element-citation></ref><ref id="B33-viruses-16-01923"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ehlers</surname><given-names>B.</given-names></name>
<name><surname>Ochs</surname><given-names>A.</given-names></name>
<name><surname>Leendertz</surname><given-names>F.</given-names></name>
<name><surname>Goltz</surname><given-names>M.</given-names></name>
<name><surname>Boesch</surname><given-names>C.</given-names></name>
<name><surname>Matz-Rensing</surname><given-names>K.</given-names></name>
</person-group><article-title>Novel simian homologues of Epstein-Barr virus</article-title><source>J. Virol.</source><year>2003</year><volume>77</volume><fpage>10695</fpage><lpage>10699</lpage><pub-id pub-id-type="doi">10.1128/JVI.77.19.10695-10699.2003</pub-id><pub-id pub-id-type="pmid">12970457</pub-id>
</element-citation></ref><ref id="B34-viruses-16-01923"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ehlers</surname><given-names>B.</given-names></name>
<name><surname>Spiess</surname><given-names>K.</given-names></name>
<name><surname>Leendertz</surname><given-names>F.</given-names></name>
<name><surname>Peeters</surname><given-names>M.</given-names></name>
<name><surname>Boesch</surname><given-names>C.</given-names></name>
<name><surname>Gatherer</surname><given-names>D.</given-names></name>
<name><surname>McGeoch</surname><given-names>D.J.</given-names></name>
</person-group><article-title>Lymphocryptovirus phylogeny and the origins of Epstein-Barr virus</article-title><source>J. Gen. Virol.</source><year>2010</year><volume>91</volume><issue-part>Pt 3</issue-part><fpage>630</fpage><lpage>642</lpage><pub-id pub-id-type="doi">10.1099/vir.0.017251-0</pub-id><pub-id pub-id-type="pmid">19923263</pub-id>
</element-citation></ref><ref id="B35-viruses-16-01923"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Correia</surname><given-names>S.</given-names></name>
<name><surname>Bridges</surname><given-names>R.</given-names></name>
<name><surname>Wegner</surname><given-names>F.</given-names></name>
<name><surname>Venturini</surname><given-names>C.</given-names></name>
<name><surname>Palser</surname><given-names>A.</given-names></name>
<name><surname>Middeldorp</surname><given-names>J.M.</given-names></name>
<name><surname>Cohen</surname><given-names>J.I.</given-names></name>
<name><surname>Lorenzetti</surname><given-names>M.A.</given-names></name>
<name><surname>Bassano</surname><given-names>I.</given-names></name>
<name><surname>White</surname><given-names>R.E.</given-names></name>
<etal/>
</person-group><article-title>Sequence Variation of Epstein-Barr Virus: Viral Types, Geography, Codon Usage, and Diseases</article-title><source>J. Virol.</source><year>2018</year><volume>92</volume><pub-id pub-id-type="doi">10.1128/JVI.01132-18</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-16-01923-f001"><label>Figure 1</label><caption><p>Identification of cyLCV miRNAs. (<bold>A</bold>) Distribution of reads aligned to cyLCV genome. (<bold>B</bold>) Positions of viral pre-miRNAs in the cyLCV genome. Red indicates experimental evidence of miRNA expression; gray indicates a predicted cyLCV pre-miRNA based on homology to the rLCV and EBV pre-miRNAs. (<bold>C</bold>) qRT-PCR analysis of three conserved viral miRNAs in primary cyLCLs established from tissue biopsies from MCM 35132. miRNA expression is shown relative to levels in Raji and rLCL 309-98 cells and normalized to miR-16. PBMCs = cyLCLs sequenced in (<bold>A</bold>); Ax LN = axillary lymph node; Ing LN = inguinal lymph node; Mes LN = mesenteric lymph node. (<bold>D</bold>) Sequence alignments of cyLCV, EBV, and rLCV miRNAs tested by qRT-PCR.</p></caption><graphic xlink:href="viruses-16-01923-g001" position="float"/></fig><fig position="float" id="viruses-16-01923-f002"><label>Figure 2</label><caption><p>Pan paniscus LCV1 miRNAs. (<bold>A</bold>) Positions of predicted viral miRNAs encoded within the Pan paniscus LCV1 genome. (<bold>B</bold>) Putative hairpin structures for eight miRNA precursors encoded within the conserved BART Cluster I.</p></caption><graphic xlink:href="viruses-16-01923-g002" position="float"/></fig><fig position="float" id="viruses-16-01923-f003"><label>Figure 3</label><caption><p>Predicted HVMA miRNAs. (<bold>A</bold>) Positions of predicted viral miRNAs encoded within the HVMA genome. (<bold>B</bold>) Putative pre-miRNA structures for the four BHRF1 miRNA homologs and miR-maL-25 encoded antisense to HVMA BALF5.</p></caption><graphic xlink:href="viruses-16-01923-g003" position="float"/></fig><fig position="float" id="viruses-16-01923-f004"><label>Figure 4</label><caption><p>CeHV12 BHRF1 miRNA homologs expressed in S594 cells. (<bold>A</bold>) Distribution of small RNA reads aligned to the baboon genome (Panu3.0) and contigs of the CeVH12 genome. 4% of reads aligned to two CeHV12 contigs that encompass the homologous BHRF1 region (AF200364.1 and AH009709.2). (<bold>B</bold>) Genome plot of small RNA sequencing reads aligned to the CeHV12 BHRF1 region. Y-axis indicates read counts (RC) (<bold>C</bold>) Putative pre-miRNA folding structures and experimentally defined 5p (colored in red) and 3p (colored in blue) sequences of the CeHV12 BHRF1 miRNAs.</p></caption><graphic xlink:href="viruses-16-01923-g004" position="float"/></fig><fig position="float" id="viruses-16-01923-f005"><label>Figure 5</label><caption><p>Identification of BART Cluster II miRNA homologs in CeHV12. (<bold>A</bold>) Schematic showing PCR primer positions and regions amplified from S594 genomic DNA. Primers correspond to miRNA sequences conserved with EBV (denoted with B) or rLCV (denoted with R). Insert: agarose gel electrophoresis following PCR amplification of CeHV12 BART regions. (<bold>B</bold>) Genome plot of reads aligned to the CeHV12 BART Cluster II region. (<bold>C</bold>) Predicted pre-miRNA folding structures with the highlighted experimentally defined 5p (colored in red) and 3p (colored in blue) sequences of the CeHV12 BART miRNAs.</p></caption><graphic xlink:href="viruses-16-01923-g005" position="float"/></fig><fig position="float" id="viruses-16-01923-f006"><label>Figure 6</label><caption><p>Detection of cyLCV miRNAs in circulation. (<bold>A</bold>) Plasma was collected from MCM 35132 (recipient) at times indicated prior to or post hematopoetic stem cell transplant (HSCT). (<bold>B</bold>) Plasma was collected from MCM 35133 (donor) at three different time points starting ~6.5 months after graft collection. For both (<bold>A</bold>,<bold>B</bold>), miRNAs were extracted from plasma samples and tested by qRT-PCR. Values are normalized to miR-16 and reported relative to the respective EBV miRNA homolog in Raji cells. RNA isolated from rLCL 309-98 and from cyLCL 35132 (spontaneously cultured out of PBMCs) were included as controls. PCR was performed in duplicate. * Student&#x02019;s <italic toggle="yes">t</italic>-test, <italic toggle="yes">p</italic> &#x0003c; 0.05.</p></caption><graphic xlink:href="viruses-16-01923-g006" position="float"/></fig></floats-group></article>